FDS - PDS Symposium IX: Speakers
Welcome |
| Julia Beaver, MD Chief of Medical Oncology, Oncology Center of Excellence US Food and Drug Administration |
| Bill Louv, PhD President Project Data Sphere |
Keynote Address: Rare cancer registries – Impact on clinical practice, drug development and regulators |
| David Fajgenbaum, MD, MBA, MSc, FCPP Assistant Professor of Medicine, Translational Medicine & Human Genetics University of Pennsylvania Medical School |
Panel 1: How do rare cancer registries impact clinical decision making? |
| Dave Reese, MD Executive Vice President, Research and Development Amgen, Inc. |
| David Miller, MD, PhD, FAAD Medical Oncologist / Massachusetts General Hospital |
| Gregory Reaman, MD Associate Director, Pediatric Oncology, Oncology Center of Excellence /US Food and Drug Administration |
| Ting Yu, MD, MS Global Medical Director /EMD Serono, A business of Merck KGaA, Darmstadt, Germany |
Panel 2: How do rare cancer registries advance drugs in development? |
| Zhen Su, MD, MBA Senior Vice President, Head of US & Global Oncology Franchise EMD Serono, A business of Merck KGaA, Darmstadt, Germany |
| Martha Donoghue, MD Pediatric Solid Tumors Scientific Liaison US Food and Drug Administration |
| Gregory Friberg, MD Vice President Global Development, Therapeutic Area Head Heme/Onc & Bone Amgen, Inc. |
| Michael Wong, MD, PhD, FRCPC Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine The University of Texas MD Anderson Cancer Center |
Fireside Chat: What is the potential of patient registries based on genomic alterations? |
| Sean Khozin, MD, MPH Vice President Global Head of Data Strategy Janssen Research & Development, LLC |
| Josh Bilenker, MD Chief Executive Officer Loxo Oncology, Inc. (a wholly owned subsidiary of Eli Lilly and Company) |
Call to Action |
| Andy Crighton, MD Chief Executive Officer CEO Roundtable on Cancer and Project Data Sphere |
